

References

1. O'Brien SG, Guilhot F, Larson RA et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med* 2003; 348:994-1004.
2. Hughes T, Kaeda J, Branford S, et al: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. *N Engl J Med* 2003;349:1423-1432
3. Druker B, Guilhot F, O'Brien S, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. *N Engl J Med* 2006; 355:2408-2417
4. Kantarjian H, Giles F, Gattermann N, et al: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. *Blood* 2007; 110:3540-3546.
5. Hochhaus A, Kantarjian H, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. *Blood* 2007; 109:2303-2309.
6. Yee KW, O'Brien SM: Chronic lymphocytic leukemia. *Mayo Clin Proc* 2006; 81:1105-1129.